Clarke takes helm at Pulmatrix as Connelly moves on

Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant (email | Twitter) and Nesa Nourmohammadi (email | Twitter) and we will feature it here each Friday.

Connelly departs Pulmatrix, Clarke takes company helm as new CEO

Over at Pulmatrix, longtime CEO Robert Connelly bid farewell and left his post at the Massachusetts biotech. His next destination: WikiCell Designs, a startup that makes edible food packaging. With Connelly gone, Pulmatrix Chief Scientific Officer Robert Clarke moves up the C-level ladder and takes on the role of CEO. With the top post filled, Pulmatrix is  focusing on generating a new round of funding to advance its COPD drug, PUR118, into Phase II. Story | Pulmatrix release | WikiCell release

Robert Connelly--Pulmatrix
Left Pulmatrix to join edible packaging startup WikiCell Designs as new CEO.


Robert Clarke--Pulmatrix
After serving as chief scientific officer, Clarke replaced Connelly as CEO.

Biotech

Civitas Therapeutics appointed Bryan Stuart as chief business officer. Release

Susan Akers-Smith was promoted to vice president of early phase oncology development at INC Research. Release

VaxInnate welcomed two new executives to its management team: Christine Mayer as vice president of business development and Katalin Abraham as vice president of regulatory affairs. Release

Aileron Therapeutics appointed Dr. Hubert Chen as vice president of clinical development. Release

NexDx welcomed Zachary Hornby and Kurt Krummel to its management team. Hornby will serve as vice president of corporate development, while Krummel will be director of molecular diagnostics and assay development. Release

Dr. Robert Martell joined Tesaro ($TSRO) as chief medical officer. Release

Navidea Biopharmaceuticals welcomed Dr. Cornelia Reininger to the role of chief medical officer. Release

Pharma

With Robert Armitage retiring from Eli Lilly ($LLY), Michael Harrington became senior vice president and general counsel. Release

Steven Gillis will join the board of directors at Shire ($SHPG) effective Oct. 1. Release

Medical Devices

Sonitus Medical named Mike Favet as chief operating officer and Jeff Mack as chief financial officer. Release

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.